Contributions
Abstract: PB2077
Type: Publication Only
Background
Myelodysplastic Syndromes (MDS) are a heterogeneous group of clonal stem cell disorders affecting mainly the elderly and characterized by ineffective haemopoiesis, peripheral blood cytopenias and risk of developing acute myeloid leukemia.
microRNAs (miRNAs) are small non coding single strand RNAs. miRNAs act inhibiting messenger RNAs (mRNAs) translation and decreasing their stability through a complementary base pairing and, on the basis of this regulatory role, abnormal miRNA levels are related to several pathological states. The presence of miRNAs in body fluids may represent a gold mine of noninvasive biomarkers in cancer. In particular, miRNAs in serum are linked with the presence of hematologic malignancies.
In MDS, immune system dysregulation may represent a primary pathophysologic abnormality and a key driver of the pathological evolution of MDS and it looks like chronic inflammation role is essential in MDS pathogenesis and progression: there is growing evidence implicating inflammation-related changes, inhibitory cytokines and increased intramedullary apoptosis as contributors to ineffective hematopoiesis.
Aims
In this study, we evaluated the expression of 15 miRNA which have been demonstrated to be dysregulated during ageing and in inflammatory conditions: miR-17; miR-9; miR-22; miR-152; miR-335; miR-19b; miR-20a; miR-34a; miR-146a; miR-181a; miR-9; miR-21; miR-126; miR-29a; miR-155.
Methods
Total RNA was isolated from the serum of 60 High Risk (HR) and Low Risk (LR) MDS patients and 30 donors and a quantitative analysis of the circulating miRNA was performed by Real Time PCR.
Results
Among 15 miRNA studied, the levels of miR-9, miR-17, miR-22, miR-34a, miR-152, and miR-335 were not detectable both in patients and donors. MiR-126, miR29a, miR20a, miR181a, 19b and miR21 show a statistically significant differential expression in both HR and LR patients with respect to controls. MiR-146a and miR-126 were altered only in LR-MDS (IPSS and R-IPSS) patients.
Conclusion
In this work it has been possible to evaluate inflamma-miRNAs’ levels in MDS. In particular, these data could have a considerable significance in LR MDS, in which inflamma-miRNAs are aberrantly expressed respect to controls and could be the key regulators in the pathogenesis of ineffective erythropoiesis and anemia and also in myeloproliferation and oncogenic transformation.
Session topic: 9. Myelodysplastic syndromes – Biology & Translational Research
Keyword(s): MDS, Myelodysplasia
Abstract: PB2077
Type: Publication Only
Background
Myelodysplastic Syndromes (MDS) are a heterogeneous group of clonal stem cell disorders affecting mainly the elderly and characterized by ineffective haemopoiesis, peripheral blood cytopenias and risk of developing acute myeloid leukemia.
microRNAs (miRNAs) are small non coding single strand RNAs. miRNAs act inhibiting messenger RNAs (mRNAs) translation and decreasing their stability through a complementary base pairing and, on the basis of this regulatory role, abnormal miRNA levels are related to several pathological states. The presence of miRNAs in body fluids may represent a gold mine of noninvasive biomarkers in cancer. In particular, miRNAs in serum are linked with the presence of hematologic malignancies.
In MDS, immune system dysregulation may represent a primary pathophysologic abnormality and a key driver of the pathological evolution of MDS and it looks like chronic inflammation role is essential in MDS pathogenesis and progression: there is growing evidence implicating inflammation-related changes, inhibitory cytokines and increased intramedullary apoptosis as contributors to ineffective hematopoiesis.
Aims
In this study, we evaluated the expression of 15 miRNA which have been demonstrated to be dysregulated during ageing and in inflammatory conditions: miR-17; miR-9; miR-22; miR-152; miR-335; miR-19b; miR-20a; miR-34a; miR-146a; miR-181a; miR-9; miR-21; miR-126; miR-29a; miR-155.
Methods
Total RNA was isolated from the serum of 60 High Risk (HR) and Low Risk (LR) MDS patients and 30 donors and a quantitative analysis of the circulating miRNA was performed by Real Time PCR.
Results
Among 15 miRNA studied, the levels of miR-9, miR-17, miR-22, miR-34a, miR-152, and miR-335 were not detectable both in patients and donors. MiR-126, miR29a, miR20a, miR181a, 19b and miR21 show a statistically significant differential expression in both HR and LR patients with respect to controls. MiR-146a and miR-126 were altered only in LR-MDS (IPSS and R-IPSS) patients.
Conclusion
In this work it has been possible to evaluate inflamma-miRNAs’ levels in MDS. In particular, these data could have a considerable significance in LR MDS, in which inflamma-miRNAs are aberrantly expressed respect to controls and could be the key regulators in the pathogenesis of ineffective erythropoiesis and anemia and also in myeloproliferation and oncogenic transformation.
Session topic: 9. Myelodysplastic syndromes – Biology & Translational Research
Keyword(s): MDS, Myelodysplasia